Meta AnalysisID 6018
丹蒌片辅助治疗冠心病的有效性与安全性：随机对照试验的系统评价
CRD42015026713
Does Danlou tablet have benefits for coronary heart disease? Does Danlou tablet often have adverse effects and events when treating coronary heart disease?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6018
- Evidence Id
- 14576
- Core Evidence Id
- 14576
- Source Meta Analysis Id
- 6001
- Herb2 Meta Analysis Id
- HBMA006001
- Crd Id
- CRD42015026713
- Title
- Efficacy and safety of adjuvant therapy of Danlou tablet for coronary heart disease: a systematic review of randomized controlled trials
- Review Question
- Does Danlou tablet have benefits for coronary heart disease? Does Danlou tablet often have adverse effects and events when treating coronary heart disease?
- Study Type Included
- Randomized controlled trials will be included in this systematic review. We will contact all the included study authors for the details of randomization methods.
- Condition Being Studied
- Coronary heart disease (coronary heart diseases, CHD) is a common clinical disease. With the prosperity of social economy, cardiovascular disease incidence in our country increased year by year. At present the means of treatment of coronary heart disease in clinic is various, but treatment with drug is still the main method. Select rational drug for treatment with great influence on prognosis. Chinese medicine (CM) has been practised for thousands of years and a series of studies have suggested that it bring multiple benefits to people with CHD due to the discovery of their effectiveness in alleviating symptoms of myocardial infarction,angina pectoris, arrhythmia, hypertension and other cardiovascular conditions. In particular, Danlou Tablet,a Chinese patent medicine, has been successfully utilized by many cardiologists and internists for its induction of promoting blood circulation and eliminating phlegm. It consists of the following ingredients: Salvia, miltiorrhiza Bunge, Ligusticum chuanxiong Hort, Trichosanthes kirilowii Maxim and Allium macrostemon Bunge, etc. There is no research on Danlou Tablet system evaluation on the treatment of coronary heart disease.
- Participant
- Patients of both sexes who have coronary heart disease, regardless of age, gender, race or educational and economic status will be included. Participants with myocardial infarction, heart failure, hepatic failure and renal failure were excluded. The diagnostic criteria coronary heart disease are explicit according to the domestic or international acknowledged diagnostic criteria.
- Animal
- Human Disease Modelled
- Intervention
- 1. Danlou tablet combined with any current Western drugs compared with the same Western drugs alone 2. Danlou tablet combined with any current Western drugs compared with placebo plus the same Western drugs
- Comparator Control
- For control, any current Western drugs and placebo. Any specific herbs extract injection and Chinese medicine are not allowed as controls.
- Main Outcome
- Cardiovascular death, non-fatal myocardial infarction, heart failure, angor pectoris, coronary revascularization
- Outcome Measure
- Additional Outcome
- Clinical efficacy, angina symptom improvement, ECG improvement, adverse effects (eg: toxic responses, anaphylaxis, any problems with veins used for intravenous administration)
- Study Method
- Keyword
- Angina Pectoris; Combined Modality Therapy; Humans; Randomized Controlled Trials as Topic; Safety; Tablets
- Contact
- Mr Zhang [email protected]
- Organisational Affiliation
- Liaoning University of traditional Chinese medicine
- Funding Source
- National Basic Research Program of China: The research stable angina pectoris resulted by Spleen deficiency generating phlegm and the study of mechanism of action and regular from spleen (2013CB531704) Science and Technology Research of Liaoning Province Department of Education: The randomized controlled trial of the systematic review and methodology evaluation research of coronary heart disease treated from spleen and traditional Chinese medicine (L2014372)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2015-09-30
- Anticipated Start Date
- 2015-09-30
- Anticipated Completion Date
- 2015-12-01
- Title Cn
- 丹蒌片辅助治疗冠心病的有效性与安全性：随机对照试验的系统评价
- Title En
- Efficacy and safety of adjuvant therapy of Danlou tablet for coronary heart disease: a systematic review of randomized controlled trials
- Bilingual Status
- complete